CURRICULUM VITAE

Maria Cristina Ghiuzeli, MD

1. PERSONAL DATA

     Place of birth:        Bucharest, Romania

2. EDUCATION

9/1995-6/1999        BS, Biochemistry, magna cum laude, University of California, Los Angeles, CA

                9/1999-6/2003        MD, Albert Einstein College of Medicine, Bronx, NY

3. POSTGRADUATE TRAINING

7/2003-6/2004        Intern in Internal Medicine, Long Island Jewish Medical Center, New Hyde Park, NY

7/2004-6/2006        Resident in Internal Medicine, Long Island Jewish Medical Center, New Hyde Park, NY

7/2006-6/2009        Fellow in Hematology/Oncology, Montefiore Medical Center, Bronx, NY

4. FACULTY POSITIONS HELD

7/2009-7/2016       Acting Instructor of Medicine, New York College of Osteopathic Medicine, Glen Head, NY

     7/2011-10/2020     Assistant Professor, Hofstra Medical School of Northwell Health,

                                    Hempstead, NY

7/2017-10/2020     Assistant Investigator, Feinstein Institute for Medical Research, Manhasset, NY          

                 12/2020-                 Clinical Associate Professor, University of Washington Medical

                                                Center, Seattle, WA   

5. HOSPITAL POSITIONS HELD

     7/2009-10/2020     Attending Physician, Monter Cancer Center (Northwell Health),   

                                    Lake Success, NY

7/2009-10/2020     Attending Physician, Northshore University Hospital (Northwell Health), Manhasset, NY

     7/2009-10/2020     Attending Physician, Long Island Jewish Hospital (Northwell Health),

                                    Manhasset, NY

     12/2020-                 Attending Physician, Fred Hutchinson Cancer Center, Seatlle, WA

     12/2020-                 Attending Physician, University of Washington Medical Center, Seattle, WA

6. HONORS

                1999                        Honors in Biochemistry, University of California, Los Angeles, CA

    1999                        Magna cum laude, University of California, Los Angeles, CA

                1999-2002               Romanian Medical Association Award (New York)

                2008-2009               Sanofi-Aventis ASCO Travel Grant Award (New York)

    2012                        Most Compassionate Doctor Award (Northwell Health, NY)

    2015-2019               Super Doctors Award (New York)

    2016-2019               Castle Connolly Top Doctors for Hematology (New York)

    2017-2020               Top Doctors Award (US News)

    2017                        Lawrence Scherr Scholarly Activity Award (Northwell Health, NY)

7. BOARD CERTIFICATION

     2006, 2016             Diplomate, American Board of Internal Medicine

     2010                       Diplomate, American Board of Internal Medicine, Oncology

     2010, 2021             Diplomate, American Board of Internal Medicine, Hematology

8. LICENSURE

                 2006-2021              New York State Medical License

                 2020-                      Washington State Medical License

9.  DIVERSITY, EQUITY AND INCLUSION ACTIVITIES

    None

10. PROFESSIONAL ORGANIZATIONS

    2003-2006               American Medical Association (AMA)

                2008-                       American Society of Clinical Oncology (ASCO) 

          2008-                       American Society of Hematology (ASH)

    2011-2015               Medical Society of the State of New York (MSSNY)

                2012-2019               American Association for Cancer Research (AACR)

    2019-2021               Association of Clinical Research Professionals (ACRP)                                

11. TEACHING RESPONSIBILITIES

    2009-2020              Fellow teaching, In and Out Clinic, Northwell Health, NY

    2009-2020               Resident teaching, In and Out Clinic, Northwell Health, NY

    2009-2020               Medical student teaching, In and Out Clinic, Northwell Health, NY

                2009-2020              Grand rounds and core lecture teaching conferences, Northwell

                                                Health, NY

    2009-2016               Lecturer, medical student hematology course, New York College of Osteopathic Medicine, NY

    2019, 2020              Lecturer, resident teaching, South Nassau Community Hospital, NY

2009-2019               Fellow teaching, weekly hematology/oncology clinic, Northwell

                                Health, NY

2020-                       Fellow teaching, In Clinic, University of Washington Medical Center,            WA

2020-                       Resident teaching, In Clinic, University of Washington Medical            

                                Center, WA

2020-                       Medical student teaching, In Clinic, University of Washington

                                Medical Center, WA

2022-                       Advanced Practitioners teaching, Outpatient Clinic, Fred Hutchinson Cancer Center, WA    

2022-2023                       Center for Leadership &Innovation in Medical Education (CLIME): Clinical Teaching Certificate course, School of Medicine (UW Medicine), WA  -completed course

12. EDITORIAL RESPONSIBILITIES

    None

13. SPECIAL RESPONSIBILITIES AND SERVICE

                2009                        Anticoagulation Quality Improvement Committee (Northwell Health)

    2009                        Electronic Medical Records Pilot Program Committee (Northwell Health)

2010                        Emergency Room Rapid Triage Program for Chemotherapy patients Committee (Northwell Health)

2010-2020               Chair/Organizer of Hematologic Malignancies Tumor Board (Northwell Health)

2013-2020               Chair/Organizer of Hematology Grand Rounds lecture series (Northwell Health)

    2015-2020               Member of Fellowship Review Committee (Northwell Health)

    2015, 2017, 2020    Judge -Northwell Health Academic Competition (Northwell Health)

    2016-2020               Chair/Organizer of Hematology weekly working Group (Northwell

                                    Health)

    2022                        Member, hiring committee for the Multiple Myeloma Clinical

                                    Faculty position

    2022                        Member, Acuity-based staffing model committee

    2022-2023               Member, clinical communications workgroup

    2023,2025               Member of hiring committee for the Acute Myeloid Leukemia

                                    Clinician Scholar position

    2023                        Member of hiring committee for Advanced Practitioner in Myeloid

                                    Neoplasms positions

14. CLINICAL ACTIVITIES

   Clinical time consists of 3 days/week of full patient visits in outpatient settting. In the

   outpatient setting, I am the clinical leader of 3 teams: the continuity team, which cares for

   patients with MDS, Acute leukemia on less intensive regimens or post treatment, MPN,

   aplastic anemia, PNH and CML, the Cedar (acute leukemia) team, which cares for patients

   with acute leukemias undergoing intensive chemotherapy regimens, and the Sequoia (post-

   transplant) team, which cares for the leukemia patients returning to us post transplant. We

   have weekly meetings, and I teach the APP/RN’s both ongoing and during the scheduled

   meetings.

   I also attend 2-3 times/academic year on inpatient acute leukemia service. During this

   time, I am involved on a daily basis in teaching the fellow/medicine residents/medical

   students, in addition to the weekly formal lectures.

15. RESEARCH FUNDING

1. Current  -partial list

2024-                     Sponsor: Oncoverity

Title: A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Role on Project: Sub-Investigator

2024-                     Sponsor: Imgen

Title: Phase 1 Study of FLAG-Ida with Pivekimab Sunirine (PVEK [IMGN632]) for Adults with Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

                                                Role on Project: Sub-Investigator

                  2023-                     Sponsor: SWOG

Title: A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T- Cell Lymphoblastic Lymphoma (T-LBL)

                                                Role on Project: Sub-Investigator

                  2024-                     Sponsor: Incyte

Title: Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab (R) + Tafasitamab-cxix for the Treatment of Newly-Diagnosed Adults with Philadelphia chromosome-negative (Ph-) B-cell Lymphoblastic Lymphoma/Leukemia (B-ALL)

Role on Project: Co-Investigator

                 2022-                      Sponsor: ECOG

Title: A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

Role on Project: Co-Investigator

                 2023-                      Sponsor: Incyte

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Role on Project: Sub-Investigator

                 2023-                      Sponsor: DISC

Title: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Role on Project: Sub-Investigator

              2023-                         Sponsor: Genentech

Title: CONCERTO: A phase 2 trial of cobimetinib in newly diagnosed or HMA-treated CMML patients with RAS pathway mutations

Role on Project: Sub-Investigator

               2024-                        Sponsor: Sumimoto Pharma

Title: A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

Role on Project: Sub-Investigator

2. Past

   Federal Grants

                2010-2013               Sponsor: CCOP/NCI

                  Title: Community Clinical Oncology Program

                                                Total costs: $1,000,000

Role on Project: Sub-Investigator

    2013-2019               Sponsor: NCORP/NCI

Title: NCI Community Oncology Research Program

Total costs: $4,187,374

Role on Project: Principal Investigator

1. 2020.             Sponsor: NCORP/NCI

Title: NCI Community Oncology Research Program

Total costs: $4,678,952

Role on Project: Principal Investigator

                Institutional Grants

    2011-2020               Sponsor: Northwell Cancer Institute Grants, Northwell Health

                  Title: A pharmacologic study of Arsenic Trioxide in Cancer patients

                                                Total costs: $50,000

Role on Project: Principal Investigator

    2013-2018               Sponsor: Northwell Cancer Institute Grants, Northwell Health

Title: A Pilot Study Treatment of Malignant Tumors using [18F] Fluorodeoxyglucose (FDG)

Total costs: $79,680

Role on Project: Sub-Investigator

                Industry Grants

    2008-2020               Sponsor: M07-001, Alexion Pharmaceuticals

                  Title: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

                                                Total costs: $26,130

                                                Role on Project: Sub-Investigator

1. 2020.             Sponsor: MSKCC 15-193, MSKCC

Title: A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Total Costs: $13,257

Role on Project: Sub-Investigator

    2019-2020               Sponsor: Role on Project: Sub-Investigator

Title: A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Total Costs: $630,271

Role on Project: Principal Investigator

    1/2020-10/2020      Sponsor: 54767414MMY3021 (AURIGA), Janssen Pharmaceuticals

Title: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Total Costs: $200,696

Role on Project: Sub-Investigator

    2011-2014               Sponsor: VOS-AML-301, Sunesis Pharmaceuticals

Title: A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical    Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)

Total Costs: $120,160

                                    Role on Project: Sub-Investigator

    2012-2020               Sponsor: CLTR0310-301, Celator Pharmaceuticals

Title: A Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML

Total Costs: $113,017

    2012-2017               Sponsor: B1931022, Pfizer

Title: An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-positive Acute Lymphoblastic Leukemia (ALL)

Total Costs: $44,742

                                                Role on Project: Sub-Investigator

Role on Project: Sub-Investigator

     2013-2018              Sponsor: ACE-011-MDS-001, Celgene Corp.

Title: An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Total Costs: $26,165

                                                Role on Project: Sub-Investigator

    2014-2017               Sponsor: CFZ001, Onyx

Title: An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease

Total Costs: $103,829

                                                Role on Project: Sub-Investigator

    2016-2017               Sponsor: 04-21, Onconova

Title: A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine

Total Costs: $45,927

                                                Role on Project: Sub-Investigator

    2016-2017               Sponsor: Pevonedistat-2001/ P-2001, Millennium Pharmaceuticals

Title: A Phase II, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and low-blast acute myelogenous Leukemia

Total Costs: $73,158

                                                Role on Project: Sub-Investigator

    2016-2018               Sponsor: GRASPALL 2012-09, Erytech Pharma

Title: A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (ERYASP) in Combination With the NCI/CALGB Regimen During Induction and Consolidation Phases for Frontline Therapy Adult Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia

Total Costs: $137,743

Role on Project: Sub-Investigator

    2016-2019               Sponsor: CNTX-CX-01-2015-AML-1, Cantex

Title: A Randomized, Phase II Study of CX-01 Combined with Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Total Costs: $108,585

Role on Project: Sub-Investigator

    2017-2018               Sponsor: ALXN1210-PNH-301, Alexion Pharmaceuticals

Title: A Phase III, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab In Complement Inhibitor-Naïve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Total Costs: $26,584

                                                Role on Project: Sub-Investigator

    2017-2018               Sponsor: ALXN1210-PNH-302, Alexion Pharmaceuticals

Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated with Eculizumab

Total Costs: $38,577

                                                Role on Project: Sub-Investigator

    2017-2020               Sponsor: INCB 391 10-301 / GRAVITAS-301, Incyte

Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or placebo in combination with corticosteroids for the treatment of First-Line acute Graft-Versus-Host Disease

Total Costs: $165,877

                                                Role on Project: Sub-Investigator

    2017-2020               Sponsor: 1315.2, Boehringer Ingelheim

Title: An open-label, Phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine in patients with acute myeloid leukemia

Total Costs: $31,301

Role on Project: Sub-Investigator

    2019-2020               Sponsor: B1371019 (BRIGHT), Pfizer

Title: A Randomized (1:1), Double-Blind, Multi-Center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF-04449913) or Azacitidine (AZA) With or Without Glasdegib in Patients With Previously Untreated Acute Myeloid Leukemia

Total Costs: $605,513

Role on Project: Sub-Investigator

    2018-2020               Sponsor: WO29519 (MIRROS), Hoffman-La Roche

Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, with Cytarabine versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Total Costs: $201,215

                  Role on Project: Sub-Investigator

    2018-2020               Sponsor: ASTX727-02 (ASCERTAIN), Astex Pharmaceuticals, Inc.

Title: A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Total Costs: $138,576

                  Role on Project: Sub-Investigator

2018-2020                   Sponsor: BGB-A317-207, BeiGene, Ltd.

Title: A Phase 2, Open-Label Study of BGB-A317 in patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms
Total Costs: $20,710

Role on Project: Sub-Investigator

            2021-2023                   Sponsor: Ascentage

Title: A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML, CMML or  MDS

                                                Role on Project: Sub-Investigator

            2021-2023                   Sponsor: Cellgene

Title: AN EXPLORATORY PHASE 1B OPEN-LABEL MULTI-ARM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CC-90009 IN COMBINATION WITH ANTI-LEUKEMIA AGENTS IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA

Role on Project: Sub-Investigator

            2021-2023                   Sponsor: Amgen

Title: A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) 

Role on Project: Co-Investigator

            2023-2024                   Sponsor: Astex

Title: A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

Role on Project: Sub-Investigator

16. BIBLIOGRAPHY

1. Publications in Peer-reviewed journals

1. Kearns-Jonker M, Swensson J, Ghiuzeli C, Chu W, Osame Y, Starnes V, Cramer DV. The Human Antibody Response to Porcine Xenoantigens Is Encoded by IGHV3-11 and IGHV3-74 IgVH Germline Progenitors. Journal of Immunology 1999 Oct 15;163 (8):4399-412. [original work]
2. Kearns-Jonker M, Swensson J, Ghiuzeli C, Chu W, Navaez A, Osame Y, Mendez R, Cramer DV. Identification of human immunoglobulin genes involved in the immune response to pig tissues. Transplantation April 1998 1(supplement). [original work]
3. Kearns-Jonker M, Swensson J, Ghiuzeli C, Chu W, Osame Y, Starnes V, Cramer DV. The human antibody response to porcine xenoantigens is encoded by IGHV3-11 and IGHV3-74 IgVH germline progenitors. The Journal of Immunology November 1999, 163(8): 4399-412. [original work]
4. Cholankeril Michelle, Bradley Thomas, Devoe Craig, Ghiuzeli Cristina, Kolitz Jonathan, Allen Steven. Successful therapy of cold agglutinin disease utilizing Rituximab. Blood, Nov 2011; 118(21):5161-5272. [case report]
5. Stanton A, Ghiuzeli C, Chapman N, Hughes A, Thom S. Human Retina Arteriolar Dilatation Occurs With Blood Pressure Lowering With Amlodipine But Not With Lisinopril. Journal of Hypertension 2002; 20 (Suppl. 4): S73. [case report]
6. Ghiuzeli C Dasatinib –Associated Transient Peripheral Blood Appearance of a Clonal Large Granular Lymphocytic Population in a Philadelphia-Positive Acute Lymphoblastic Leukemia Patient: A Case Report. Romanian Journal of Oncology and Hematology; March 2014. [case report]
7. Daniel W. Ross, Rimda Wanchoo, Adriana Guigova, Cristina Ghiuzeli, Steven L. Allen, Kenar D. Jhaveri. Light chain Fanconi syndrome in a patient with acute myeloid leukemia and monoclonal gammopathy of undetermined significance. Clinical and Experimental Nephrology (CEN)  Case Reports, pg 1-4. First online: 30 August 2016. [case report]
8. Lee A., Greaves G., Lee R., Zdravkova M., Ahmad S., McGovern K., Ghiuzeli, C., Hymowitz M. Bilateral angle closure following the infusion of a monoclonal antibody to treat relapsing multiple myeloma. J. Glaucoma. 2018 May 31. [case report]
9. Sharma, Sandhya; Garg, Natasha ; Ghiuzeli, Cristina. An Unusual Case of Dasatinib associated acute bilateral Hyphemas leading to blindness in a patient with Chronic Myeloid Leukemia. BMJ Case Rep. 2018 Aug 27;2018. pii: bcr-2018-225705. doi: 10.1136/bcr-2018-225705. [case report]
10.  Chung Su Yun, Shen Janice Gloria, Ghiuzeli Cristina. Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia. BMJ Case Reports Sept 2020; 13(9). [case report]
11. Barsoum Barbara, Henneman Amrita, Ahmad Samrah, Ghiuzeli Cristina. Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia. Leukemia and Lymphoma October 2020. [original work]
12. Giannis Dimitrios, Allen Steven, Davidson Anne, Marder Galina, Flint Sarah, Garrett David, Thakur Richa, Snyder Matthew, Ghiuzeli Cristina, McGinn Thomas, Davidson Karina, Qiu Michael, Barish Matthew, Spyropoulos Alex. Thromboembolic outcomes of hospitalized COVID-19 patients in the 90-day post-discharge period: early data from the Northwell CORE-19 registry. Blood November 2020; 136(Supplement 1): 33-34. [original work]
13. Paul Doru, Ghiuzeli Cristina, Rini Josephine, Fung Edward, Ghali Maged, Ben-Levi Eran, Prideaux Andrew, Vallabhajosula Shankar, Popa Elizabeta. A pilot study treatment of malignant tumors using low-dose 18F-fluorodeoxyglucose (18F-FDG). American Journal of Nuclear Medicine and Molecular Imaging, December 2020; 10(6):336-341. [original work]
14. Ghiuzeli CM, Stýblo M, Saunders J, Calabro A, Budman D, Allen S, Devoe C, Dhingra R. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients. Leuk Lymphoma. 2021 Oct 25:1-11. doi: 10.1080/10428194.2021.1978084. [original work]
15. Xinmin Zhang, C. Ghiuzeli, Erin Jou, P. Hsu, J. Kolitz, J. Bordy. CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: an age-related disease with unfavorable prognosis. Leukemia Research Reports 2022 June 25;17:100334. Doi: 10.1016/j.lrr.2022.100334. [case report]
16. Lucas Zarling, P. Stevenson, Lorinda Soma, H. Martino, Mary-Elizabeth Percival, Anna Halpern, Cristina Ghiuzeli, Pamela Becker, Vivian Oehler, Jason Cooper, Johnnie Orozco, Paul Hendrie, Roland Walter, Elihu Estey, Ryan Cassaday. Dose-adjusted EPOCH versus Hypercvad as initial treatment for adults with acute lymphoblastic leukemia (ALL): a retrospective matched cohort comparison. Bloood (2022) 140 (Supplement 1): 6046-6048. [original work]
17. A. Halpern, E. Rodriguez-Alboli, M. Othus, Kelsey-Leigh A. Garcia, M Percival, R. Cassaday, V. Oehler, P Becker, Jacob Appelbaum, J. Abkowitz, J. Orozco, S. Keel, P. Hendrie, B. Scott, C. Ghiuzeli, R. Walter, E. Estey. Addition of sorafenib to cladrabine, high dose cytarabine, G-CSF, and mitoxanthrone (CLAG-M) in adults with newly-diagnosed acute myeloid leukemia (AML) and high-grade myeloid neoplasms independent of FLT-3 mutation status: final results of a phase ½ study. Blood 2022. [original work]
18. R. Cassaday, Kelsey-Leigh Garcia, T. Gooley, C. Martino, M. Percival, A. Halpern, V. Oehler, J. Abkowitz, R. Walter, C. Ghiuzeli, E. Estey. P351: dose-adjusted EPOCH + Inotuzumab ozogamicin (DA-EPOCH-INO) is safe and active in adults with relapsed/refractory (R/R) B lymphoblastic leukemia (B-ALL): initial results of a phase 1 trial. Medicine Journal, 2022. [original work]
19. Noam Kopmar, Xiaoyu Qu, Yajuan Liu, Ted Gooley, Lucas Zarling, Mary-Elizabeth Perciva, Cristina Ghiuzeli, Min Fang, Ryan Cassaday. Prognostic significance of chromosomal genomic array testing in adults with newly diagnosed acute lymphoblastic leukemia. Blood 2022 140 (Supplement 1): 9196-9197. [original work]
20. Catherine Liu, Leah Yoke, Pooja Bhattacharyya, Ryan Cassaday, Zahra Kassamali Escobar, Cristina Ghiuzeli, Denise McCulloch, Steven Pergam, Pavitra Roychoudhury, Frank Tverdek, Joshua Schiffer, Emily Ford. Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 (COVID-19) Infection with Extended Duration Nirmatrelvir/Ritonavir among Outpatients with Hematologic Malignancy. Open Forum Infectious Diseases, Volume 10, Issue 6, June 2023.ofad 306, pg 1-4.
21. Anna Halpern, Eduardo Rodriguez-Arboli, Megan Othus, Kelsey-Leigh Garcia, Mary-Elizabeth Percival, Ryan Cassaday, Vivian Oehler, Pamela Becker, Jacob Appelbaum, Janis Abkowitz, Johnnie Orozco, Sioban Keel, Paul Hendrie, Bart Scott, Cristina Ghiuzeli, Elihu Estey, Roland Walter. Phase 1/2 Study of Sorafenib Added to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone in Untreated AML. Blood Advances 2023; 7(17):4950-4961 [original work]
22. Lucas Zarling, Philip Stevenson, Lorinda Soma, Christen Martino, Mary-Elizabeth Percival, Anna Halpern, Cristina Ghiuzeli, Pamela Becker, Vivian Oehler, Jason Cooper, Johnnie Orozco, Paul Hendrie, Roland Walter, Elihu Estey, Ryan Cassaday. Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia. European Journal of Hematology 2023: 111(6):863-871 [original work]
23. Noam Kopmar, Kim Quach, Ted Gooley, Christen Martino, Sindhu Cherian, Mary-Elizabeth Percival, Anna Halpern, Cristina Ghiuzeli, Vivian Oehler, Janis Abkowitz, Roland Walter, Ryan Cassaday. Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2024;10(7):961-965. [original work]

2. Meeting Abstracts and Presentations

1. 1999: M. Kearns-Jonker, J. Swensson, Cristina Ghiuzeli, W. Chu, Y. Osame, V. Starnes and D. Cramer.  Identification of Immunoglobulin Genes That Encode Human Antibody Responses to Pig Tissues. International Immunology Conference in Toronto, 1999.
2. 2009: Cristina Ghiuzeli, Evanthia T. Roussos, Jeffrey B. Wyckoff, Daqian Sun,Yarong Wang, Tania Patsialou, Sumanta Goswami, Frank B. Gertler, John S. Condeelis.  Evaluation of Mena Isoforms as a Surrogate for Epithelial Mesenchymas Transformation and Erlotinib Resistance in Breast Carcinoma.  American Society of Clinical Oncology, Annual Meeting in Orlando, Florida 2009, Abstract no: 35482, abstract ID: 1078.  Poster presented on 6/1/09.
3. 2001: Stanton A, Ghiuzeli C, Chapman N, Hughes A, Thom S.  Greater Human Retinal Arteriolar Dilatation Occurs With Blood Pressure Lowering With Amlodipine Than With Lisinopril. International Society of Hypertension, 2001
4. 2012: Michelle Cholankeril, Thomas Bradley, Craig Devoe, Cristina Ghiuzeli, Jonathan Kolitz, Steven Allen. Successful Therapy of Cold Agglutinin Disease Utilizing Rituximab. American Federation of Medical Research, Eastern Regional Meeting in Washington DC 2012.
5. 2013: Nolyn Nyatanga, Thomas Bradley, Cristina Ghiuzeli. Thrombotic Thrombocytopenic Purpura associated with Ticagrelor. Abstract presented to North Shore University Hospital Academic Competition, 2013.
6. 2013: Cristina M. Ghiuzeli, Anthony Calabro, Randall Jesse Saunders, Daniel R. Budman, Mirek Stýblo, Craig Devoe, Steven Allen. Arsenic Trioxide: Pharmacokinetics in Acute Promyelocytic Leukemia (APL) patients. American Society of Clinical Oncology, Annual Meeting in Chicago 2013, Abstract no: 112429, abstract ID: 7055. Poster presented on 6/2/13.
7. 2015: Daniel Ross, Steven Allen, Cristina Ghiuzeli, Kenar Jhaveri, Rimda Wanchoo. Light Chain Fanconi Syndrome in a Patient with Acute Myeloid Leukemia and MGUS. Poster 92 presented at the National Kidney Foundation 2015 Spring Clinical Meeting in Dallas, Texas.
8. 2015:  Mirek Stýblo, Anthony Calabro, Randall Jesse Saunders, Zuzana Drobna, Daniel R. Budman, Craig Devoe, Steven Allen Cristina M. Ghiuzeli. Metabolism and Disposition of Arsenic in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide (ATO). Abstract and poster presentation (number 1971) at  Society of Toxicology (SOT) annual meeting in San Diego, California in March 2015
9. 2015: D. Paul, C. Ghiuzeli, N. Kohn, D. Timony, R. Buro-Cavasinni, M. Aziz, O. Rafael, H. Raftopoulos, L. Glassman.  Long Term Survival of Patients with Metastatic Adenocarcinoma of the Lung in the Era of Targeted Agents. 16^th World Conference on Lung Cancer September 2015 in Denver, Colorado of the International Association for the Study of Lung Cancer (IASLC), Abstract 1307
10. 2016: Cox BW, Vallabhajosula S, Rini J,  Ghiuzeli CM, Wang L, Kapur A, Potters L, Antony J, Kamvosoulis P, Brown K, Connelly E, Stieb J, Gaballa H, Ben-Levi E,  Palestro CJ and Paul D. A Phase I Dose Escalation Study of Targeted Radionuclide Therapy of Malignant Tumors Using ¹⁸F Fluorodeoxyglucose (¹⁸F-FDG): Initial Experience & Early Results. Abstract presented at ASTRO in 2016
11. 2016: Doru Paul, Shankar Vallabhajosula, Ghiuzeli Cristina, Josephine Rini, Ajay Kapur, Maged Ghaly, Eran Ben Levi, Chris Palestro, Lin Wang, Jose Antony, Panagiotis Kamvosoulis, Hani Gaballa, Elizabeth Connelly and Brett Cox. Targeted radionuclide therapy of malignant tumors using [18F] Fluorodeoxyglucose (FDG): A Phase 1 dose escalation clinical trial.  J Nucl Med May 1, 2016 vol. 57 no. supplement 2 247. Abstract 247. Presented at the oral sessions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting
12. 2017: Doru Paul, Josephine Rini, Cristina Ghiuzeli, Eran Ben-Levi, Brett Cox, Ajay Kapur, Chris Palestro, Shankar Vallabhajosula. Targeted radionuclide treatment of cancer using [18F] Fulorodeoxyglucose (FDG): A Phase 1 Dose escalation clinical tiral. Oral presentation at the Next Generation Cancer Clinical Trials held on October 13^th, 2017 at Cold Spring Harbor, NY
13. 2017: Mohammed Khan, Sara Tariq, Cristina M. Ghiuzeli, Mirek Stýblo, Anthony Calabro, Randall Jesse Saunders, Daniel R. Budman, Craig Devoe, Steven Allen. Arsenic trioxide metabolism in patients with acute promyelocytic leukemia.  Presented at poster session of AACR Annual Meeting 2017 in Washington, D.C. on 4/5/17 Abstract # 2655
14. 2017: Cristina M. Ghiuzeli. Dasatinib-Associated Acute Bilateral Hyphemas Leading to Blindness in a Newly Diagnosed Patient with Chronic Myeloid Leukemia: A Case Report. Abstract #201. Presented as a poster at the10th International Congress on Myeloproliferative Neoplasms and Chronic Myeloid Leukemia, held November 2-3, 2017 at the InterContinental NY Times Square in New York, New York
15. 2020: Chung, Su Yun; Shen, Janice; Ghiuzeli, Cristina. Vemurafenib-induced Pancreatitis in a Patient with Recurrent Hairy Cell Leukemia. BMJ Case Reports 2020 Sept 14; 13(9) e236073. PMID 32928833
16. 2020: Barsoum B, Amrita Henneman, Samrah Ahmad, Cristina Ghiuzeli. Evaluation of the Efficacy and Safety of Arsenic Trioxide Dosing in Obese Patients with Acute Promyelocytic Leukemia. Leukemia and Lymphoma 2020 Oct 27:1-6. PMID 33107373
17. Jennifer Huang, Jacob Appelbaum, Kathryn Russell, Carole Shaw, Ashley Eckel, Xueyan Chen, Rutu Vyas, Paul Hendrie, Anna Halpern, Raya Mawad, Ryan Cassaday, Roland Walter, Mary-Elizabeth Percival, Cristina Ghiuzeli. Treatment Outcomes for Adults with Mixed Phenotypic Acute Leukemia: A Large Single-Center Retrospective Study. Blood 2023; 142 (Supplement 1): 2838-2838
18. Michelle Zhang, Carole Shaw, Kathryn Russell, Rutu Vyas, Anna Halpern, Jacob Appelbaum, Cristina Ghiuzeli, Roland Walter, Mary-Elizabeth Percival. Evaluation of ECOG Performance Status at Diagnosis and Relapse in Patients with Acute Myeloid Leukemia. Blood 2023: 142 (supplement 1): 2844-2844
19. Noam Kopmar, Kim Quach, Ted Gooley, Christen Martino, Sindhu Cherian, Mary-Elizabeth Percival, Anna Halpern, Cristina Ghiuzeli, Vivian Oehler, Janis Abkowitz, Elihu Estey, Ryan Cassaday. A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL). Journal of Clinical Oncology 2023; 41(16 suppl):7007-7007
20. Matthew Wu, Katie Russell, Carole Shaw, Anna Halpern, Cristina Ghiuzeli, Jacob Appelbaum, Paul Hendrie, Roland Walter, Mary-Elizabeth Percival. Evaluation of cardiac failure and recovery in acute myelogenous leukemia. Journal of Clinical Oncology 2023; 41 (16 suppl): 7038-7038
21. Michelle Zhang, Carole Shaw, Katie Russel, Anna Halpern, Jacob Appelbaum, Paul Hendrie, Cristina Ghiuzeli, Roland Walter, Mary-Elizabeth Percival.

Effect of change in ECOG performance status at diagnosis and relapse in patients with acute myeloid leukemia. Journal of Clinical Oncology 2023; 41 (16 suppl): e19007-e19007

22. Jennifer Huang, Jacob Appelbaum, Kathryn Russell, Carole Shaw, Ashley Eckel, Xueyan Chen, Rutu Vyas, Paul Hendrie, Anna B. Halpern, Raya Mawad, Ryan Cassaday, Roland Walter, Mary-Elizabeth Percival, Cristina Ghiuzeli. Hematopoietic stem cell transplant for adults with mixed phenotypic acute leukemia. Journal of Clinical Oncology 2024; 42(16 suppl): 6517-6517
23. Suravi Raychaudhuri, Ted Gooley, Zach Gill, Allegra Rasmussen, Anna Halpern, Jacob Appelbaum, Cristina Ghiuzeli, Paul Hendrie, Ryan Cassaday, Roland Walter, Elihu Estey, Mary-Elizabeth Percival. Phase I Trial Combining Venetoclax with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients with High-Grade Myeloid Neoplasms. Blood 2023; 142 (Supplement 1): 2897-2897
24. Esther Chong, Bowon Joung, Durga Cherukuri, Yan Liu, Saied Mirshahidi, Jane Xu, Jeffery Xiao, Xi Huang, Cristina Ghiuzeli, David Baylink, Qian Liu, Xuelian Chen, Homa Dadrastoussi, Julian Olea, Kaijin Wu, Kevin Kelly, Xi Zhang, Fengzhu Sun, Mojtaba Akhtari, Cao Huynh, Yi Xu. Detection of Cryptic Gene Fusion and Chimeric RNA Variants in Relapsed/Refractory Acute Myeloid Leukemia Patients Diagnosed with KMT2A/Afdn Chromosomal Translocation. Blood 2023; 142 (suppl 1): 5994-5994

17. OTHER

    2009, 2010        Invited speaker. “Ask the Doctor”, Leukemia and Lymphoma Society (NY)

    2015, 2016        Invited speaker. “Ask the Doctor”, Lymphoma Society (NY)

    2018                  Invited speaker.  STOP Cancer: 2^nd international Translational Symposium for Personalized Oncology. Title: “New Therapies in Acute Myeloid Leukemia” 4/14/18 (Bucharest, Romania)

2022                  Invited speaker. STOP Cancer Conference. Title: “Leukemia and lymphoma highlights” 5/19/22 (via Zoom; live conference in Bucharest, Romania)

2023                  Invited speaker. Integrated Biomedical Science Seminar Series. Title: “AML: Past, present and future directions.” 4/6/23. Loma Linda University (Loma Linda, CA)

2024                  Invited speaker, STOP Cancer Conference. Title: “Acute Myeloid Leukemia” 7/18/24 (via Zoom, live conference in Bucharest, Romania)